MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Accrued expenses and other curre...
Noncash rent expense
Others
Negative Cash Flow Breakdown
Purchases of investments
Accounts payable
Non-current operating lease liab...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-9,905
-9,036
-15,116
-8,498
Stock-based compensation expense
1,511
1,447
1,412
1,739
Depreciation expense
28
27
66
86
(accretion) amortization on investments
170
162
149
292
(gain) loss on sale of investments
0
-
71
0
Impairment of right-of-use assets and property and equipment
-
-
7,348
-
Noncash rent expense
550
546
714
791
(gain) loss on sale of equipment
0
0
3
1
Prepaid expenses and other current assets
42
921
251
-475
Other non-current assets
256
-44
-44
-44
Accounts payable
-1,565
2,390
-396
204
Accrued expenses and other current liabilities
2,874
-3,587
582
-1,464
Non-current operating lease liabilities
-993
-980
-967
-934
Net cash provided by (used in) operating activities
-7,968
-10,232
-6,787
-7,850
Proceeds from sale of equipment
0
0
3
1
Proceeds from sales and maturities of investments
15,000
19,500
33,011
23,500
Purchases of investments
18,124
0
35,903
14,911
Net cash provided by (used in) investing activities
-3,124
19,500
-2,889
8,590
Proceeds from exercise of common stock options and espp, net of restricted stock surrendered for taxes
217
-185
-196
50
Proceeds from issuance of common stock, net of issuance costs
-
-
0
0
Net cash provided by (used in) financing activities
217
-185
-196
134
Net (decrease) increase in cash and cash equivalents
-10,875
9,083
-9,872
874
Cash, cash equivalents and restricted cash, beginning of period
30,902
21,819
31,691
37,256
Cash, cash equivalents and restricted cash, end of period
20,027
-
-
-
Cash and cash equivalents, end of period
19,194
-
-
-
Restricted cash, end of period
833
-
-
-
Cash, cash equivalents and restricted cash, end of period
20,027
30,902
21,819
31,691
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
common stock options...
$217K
(358.33%↑ Y/Y)
Net cash provided by
(used in) financing...
$217K
(358.33%↑ Y/Y)
Net (decrease)
increase in cash and cash...
-$10,875K
(-68.89%↓ Y/Y)
Canceled cashflow
$217K
Accrued expenses and
other current...
$2,874K
(640.23%↑ Y/Y)
Stock-based compensation
expense
$1,511K
(-56.54%↓ Y/Y)
Noncash rent expense
$550K
(-64.49%↓ Y/Y)
Depreciation expense
$28K
(-83.82%↓ Y/Y)
Proceeds from sales and
maturities of investments
$15,000K
(-76.03%↓ Y/Y)
Net cash provided by
(used in) operating...
-$7,968K
(-118.01%↓ Y/Y)
Net cash provided by
(used in) investing...
-$3,124K
(93.83%↑ Y/Y)
Canceled cashflow
$4,963K
Canceled cashflow
$15,000K
Net income (loss)
-$9,905K
(-121.54%↓ Y/Y)
Purchases of investments
$18,124K
(-83.99%↓ Y/Y)
Accounts payable
-$1,565K
(51.64%↑ Y/Y)
Non-current operating lease
liabilities
-$993K
(45.20%↑ Y/Y)
Other non-current
assets
$256K
(390.91%↑ Y/Y)
(accretion) amortization on
investments
$170K
(-79.71%↓ Y/Y)
Prepaid expenses and
other current assets
$42K
(-92.67%↓ Y/Y)
Buy us a coffee
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)